Markels John 4

What Happened

• John Markels, a member of the Board of Directors of Arcturus Therapeutics Holdings, received a grant/award of 15,000 shares on 2026-06-05. The reported acquisition price is $0.00, so no cash changed hands at grant. This transaction is reported as a derivative award (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Filing date (Form 4): 2026-06-15 (filed 10 days after the transaction; Form 4s are normally due within 2 business days).
• Shares/units granted: 15,000; reported acquisition price: $0.00; total reported cash value: $0.
• Shares owned after transaction: not specified in the filing.
• Footnote: The award vests monthly over a one-year period from the grant date and represents Markels’ 2026 annual board grant.
• Transaction type: Award/grant of derivative securities (code A).

Context

• This is a routine board compensation grant, not a market purchase or sale. The award vests over 12 months, so underlying shares will become owned gradually; it does not reflect an immediate sale or cash exercise.
• Such board grants are common and primarily reflect compensation arrangements rather than a direct signal about near-term company prospects.